<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003432</url>
  </required_header>
  <id_info>
    <org_study_id>2030</org_study_id>
    <secondary_id>IRB 2030</secondary_id>
    <secondary_id>CDR0000066458</secondary_id>
    <nct_id>NCT00003432</nct_id>
  </id_info>
  <brief_title>Immunotherapy in Treating Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I/II Study of Active Immunotherapy With Carcinoembryonic Antigen RNA-Pulsed, Autologous Cultured Dendritic Cells for Patients With Breast Cancer Who Achieve a Complete Response After High Dose Chemotherapy and Stem Cell Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Immunotherapy using CEA-treated white blood cells may help a person's body build&#xD;
      an immune response to and kill their tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of immunotherapy with CEA-treated white&#xD;
      blood cells in treating patients with metastatic breast cancer who have achieved a partial or&#xD;
      complete response after chemotherapy and peripheral stem cell transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the ability of active immunotherapy with carcinoembryonic antigen (CEA) RNA&#xD;
           pulsed dendritic cells to induce CEA specific T cells in patients with metastatic breast&#xD;
           cancer in complete remission following peripheral blood stem cell transplant.&#xD;
&#xD;
        -  Determine the clinical efficacy in terms of overall and recurrence free survival of&#xD;
           immunotherapy with CEA RNA pulsed dendritic cells in this patients population.&#xD;
&#xD;
      OUTLINE: Dendritic cells are taken from the leukapheresis product obtained during the&#xD;
      peripheral blood stem cell transplant procedure performed prior to treatment on this study.&#xD;
      The dendritic cells are pulsed with carcinoembryonic antigen (CEA) RNA. Approximately 60-90&#xD;
      days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed&#xD;
      dendritic cells IV every 3 weeks for a total of 4 doses. Patients undergo a second&#xD;
      leukopheresis after the last dose of immunotherapy to obtain specimens for immunologic tests.&#xD;
&#xD;
      Patients are followed every 3 months for the first year and annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14-26 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>June 1998</start_date>
  <completion_date type="Actual">November 2002</completion_date>
  <primary_completion_date type="Actual">November 2002</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the ability of active immunotherapy with carcinoembryonic antigen (CEA) RNA pulsed dendritic cells to induce CEA specific T cells in patients with metastatic breast cancer in complete remission following peripheral blood stem cell transplant.</measure>
    <time_frame>Following administration of 4 IV vaccine doses (1 vaccine administered every 3 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the clinical efficacy in terms of overall and recurrence free survival of immunotherapy with CEA RNA pulsed dendritic cells in this patients population.</measure>
    <time_frame>Following administration of 4 IV vaccine doses (1 vaccine administered every 3 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>carcinoembryonic antigen RNA-pulsed DC cancer vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>carcinoembryonic antigen RNA-pulsed DC cancer vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>carcinoembryonic antigen RNA-pulsed DC cancer vaccine</intervention_name>
    <description>Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses.</description>
    <arm_group_label>carcinoembryonic antigen RNA-pulsed DC cancer vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic breast cancer that expresses carcinoembryonic&#xD;
             antigen (CEA)&#xD;
&#xD;
               -  At least 25% of the tumor cells must stain positive for CEA with at least&#xD;
                  moderate intensity&#xD;
&#xD;
          -  Must have achieved either partial response or complete response after high dose&#xD;
             chemotherapy and peripheral blood stem cell transplant&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1000/mm^3&#xD;
&#xD;
          -  Absolute lymphocyte count at least 1000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 mg/dL&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  No serious ongoing chronic or acute hepatic disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No serious ongoing chronic or acute cardiac disease (New York Heart Association class&#xD;
             III or IV)&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No serious ongoing chronic or acute pulmonary illness such as asthma, chronic&#xD;
             obstructive pulmonary disease, or radiation or drug induced pneumonitis&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior or concurrent malignancy except nonmelanoma skin cancer or controlled&#xD;
             superficial bladder cancer within the past 5 years&#xD;
&#xD;
          -  No history of autoimmune disease such as inflammatory bowel disease, systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, ankylosing spondylitis, scleroderma, or multiple&#xD;
             sclerosis&#xD;
&#xD;
          -  No inflammatory bowel condition such as active infectious enteritis or eosinophilic&#xD;
             enteritis&#xD;
&#xD;
          -  No active acute or chronic infection such as urinary tract infection, HIV, or viral&#xD;
             hepatitis&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 4 weeks since steroids&#xD;
&#xD;
          -  No concurrent steroid therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent immunosuppressive agents such as azathioprine or cyclosporine A&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert K. Lyerly, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 24, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2003</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

